Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

被引：180

作者：

Fabian, Denise ^{[1
]}

Eibl, Maria del Pilar Guillermo Prieto ^{[2
]}

Alnahhas, Iyad ^{[2
]}

Sebastian, Nikhil ^{[1
]}

Giglio, Pierre ^{[2
]}

Puduvalli, Vinay ^{[2
]}

Gonzalez, Javier ^{[2
]}

Palmer, Joshua D. ^{[2
]}

机构：

[1] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Dept Neurooncol, Columbus, OH 43210 USA

来源：

CANCERS | 2019年 / 11卷 / 02期

关键词：

glioblastoma; GBM; tumor treating fields; TTF; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; ADJUVANT TEMOZOLOMIDE; TTFIELDS; TRIAL; COST; SURVIVAL; THERAPY; CHEMOTHERAPY; CARE;

D O I：

10.3390/cancers11020174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

引用

页数：12

共 35 条

[11] Safety of tumor treating fields and concomitant radiotherapy for newly diagnosed glioblastoma [J].

Grossman, Rachel ;

Bukstein, Felix ;

Blumenthal, Deborah T. ;

Ben Harush, Carmit ;

Limon, Dror ;

Ram, Zvi .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[12] Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis [J].

Guzauskas, Gregory F. ;

Pollom, Erqi L. ;

Stieber, Volker W. ;

Wang, Bruce C. ;

Garrison, Lou .

CANCER RESEARCH, 2018, 78 (13)

[13] Tumor-Treating Fields Answering the Concern About Quality of Life [J].

Halasz, Lia M. ;

Mitin, Timur .

JAMA ONCOLOGY, 2018, 4 (04) :504-505

[14] Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches [J].

Hesketh, PJ ;

Batchelor, D ;

Golant, M ;

Lyman, GH ;

Rhodes, N ;

Yardley, D .

SUPPORTIVE CARE IN CANCER, 2004, 12 (08) :543-549

[15]

Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1

[16]

Kanner AA, 2013, NEURO-ONCOLOGY, V15, P114

[17] Disruption of cancer cell replication by alternating electric fields [J].

Kirson, ED ;

Gurvich, Z ;

Schneiderman, R ;

Dekel, E ;

Itzhaki, A ;

Wasserman, Y ;

Schatzberger, R ;

Palti, Y .

CANCER RESEARCH, 2004, 64 (09) :3288-3295

[18] Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors [J].

Kirson, Eilon D. ;

Dbaly, Vladimir ;

Tovarys, Frantisek ;

Vymazal, Josef ;

Soustiel, Jean F. ;

Itzhaki, Aviran ;

Mordechovich, Daniel ;

Steinberg-Shapira, Shirley ;

Gurvich, Zoya ;

Schneiderman, Rosa ;

Wasserman, Yoram ;

Salzberg, Marc ;

Ryffel, Bernhard ;

Goldsher, Dorit ;

Dekel, Erez ;

Palti, Yoram .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (24) :10152-10157

[19] Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients [J].

Mehta, M. ;

Wen, P. ;

Nishikawa, R. ;

Reardon, D. ;

Peters, K. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 :60-65

[20] Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe) [J].

Mrugala, Maciej M. ;

Engelhard, Herbert H. ;

Tran, David Dinh ;

Kew, Yvonne ;

Cavaliere, Robert ;

Villano, John L. ;

Bota, Daniela Annenelie ;

Rudnick, Jeremy ;

Sumrall, Ashley Love ;

Zhu, Jay-Jiguang ;

Butowski, Nicholas .

SEMINARS IN ONCOLOGY, 2014, 41 :S4-S13

← 1 2 3 4 →